Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 1037 results for criteria

  1. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

    NICE guideline
    Last updated
    29 June 2022
    View recommendations

    Sections for NG28

  2. Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA803

  3. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA199

  4. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome TS ID 11820

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over TS ID 11891

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Riluzole oral film for treating amyotrophic lateral sclerosis TS ID 11779

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations TSID 12011

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments TSID 11969

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears TSID8472

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Rezafungin for untreated invasive candidiasis TS ID 10768

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

    Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA812

  13. IgPro20 for treating dermatomyositis TS ID 12014

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

    Technology appraisal guidance
    Published
    26 January 2016
    View recommendations

    Sections for TA375

  15. Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Last updated
    1 November 2010
    View recommendations

    Sections for TA86